EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access

Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group

Benjamin J Huang iD, Lauren K Meyer, Todd A Alonzo, Yi-Cheng Wang, Adam J Lamble iD, Rhonda E Ries, Weijie Wang iD, Betsy Hirsch, Gordana Raca, Xiaotu Ma, Alan S Gamis iD, Richard Aplenc iD und 8 weitere

Journal of Clinical Oncology · 10.06.2025 · 43 (17) · 1961-1971

DOI: 10.1200/jco-24-01841 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2025. Verfasst von Benjamin J Huang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Hematopoietic stem cell transplantation (HSCT) is used as consolidation for pediatric patients with high-risk AML in first complete remission (CR1). The definition of high-risk AML has evolved considerably over the past two decades with the successive identification of new unfavorable risk factors. We conducted a cross-study analysis to determine whether HSCT improves the outcomes of patients with contemporarily defined high-risk AML. METHODS We combined data from AAML0531 and AAML1031, the last two phase III clinical trials completed by the Children's Oncology Group (COG). These two trials established the prognostic importance of measurable residual disease (MRD) and several high-risk cryptic cytogenetic/molecular (CM) alterations, which were applied to reclassify patients in the current COG phase III clinical trial, AAML1831. We compared the outcomes after HSCT in CR1 with those after chemotherapy alone in CR1 in the redefined high-risk group. RESULTS Our study cohort comprised 463 patients with high-risk CM alterations and 72 patients with standard-risk (SR) CM results with positive MRD at end of induction I. In all, 33.9% and 45.8% of these groups underwent HSCT in CR1, respectively. HSCT was associated with decreased relapse and improved disease-free survival (DFS) in both groups. In the high-risk CM group, 5-year DFS was 26.0% (95% CI, 20.6 to 31.6) and 49.8% (95% CI, 41.7 to 57.4; P < .001) in patients receiving chemotherapy alone and HSCT, respectively. In the SR CM and MRD+ groups, DFS was 16.9% (95% CI, 4.3 to 36.7) compared with 50.9% (95% CI, 32.7 to 66.5; P = .032). HSCT was also associated with improvement in outcomes based on multivariable analysis and across subgroups defined by clinical trial and by high-risk CM subtype, with the exception of chromosome 7 or 5 loss. CONCLUSION HSCT was associated with improved outcomes in pediatric patients with contemporarily defined high-risk AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteHumansChildMaleFemaleChild, PreschoolAdolescentNeoplasm, ResidualInfantTreatment OutcomeRisk FactorsDisease-Free SurvivalRemission Induction

Autor:innen und Institutionen

  • Department of Pediatrics, University of California San Francisco, San Francisco, CA.
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
  • Department of Pediatrics, University of Washington, Seattle, WA.
  • Department of Population and Public Health Sciences, University of Southern CA, Los Angeles, CA.
  • Children's Oncology Group, Monrovia, CA.
  • Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA.

ORCID-Profile: Benjamin J Huang, Adam J Lamble, Weijie Wang, Alan S Gamis, Richard Aplenc, E Anders Kolb, Todd M Cooper, Katherine Tarlock, Michael R Loken

Förderung

  • NCI NIH HHS

Zitieren

APA

Huang, B. J., Meyer, L. K., Alonzo, T. A., Wang, Y. C., Lamble, A. J., Ries, R. E., Wang, W., Hirsch, B., Raca, G., Ma, X., Gamis, A. S., Aplenc, R., Kolb, E. A., Cooper, T. M., Tarlock, K., Loken, M. R., Meshinchi, S., Chewning, J. H., Woods, W. G., & Horan, J. T. (2025). Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 43(17), 1961-1971. https://doi.org/10.1200/jco-24-01841

Vancouver

Huang BJ, Meyer LK, Alonzo TA, Wang YC, Lamble AJ, Ries RE, et al. Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 2025;43(17):1961-1971. doi:10.1200/jco-24-01841

BibTeX
@article{Huang2025,
  author = {Huang, Benjamin J and Meyer, Lauren K and Alonzo, Todd A and Wang, Yi-Cheng and Lamble, Adam J and Ries, Rhonda E and Wang, Weijie and Hirsch, Betsy and Raca, Gordana and Ma, Xiaotu and Gamis, Alan S and Aplenc, Richard and Kolb, E Anders and Cooper, Todd M and Tarlock, Katherine and Loken, Michael R and Meshinchi, Soheil and Chewning, Joseph H and Woods, William G and Horan, John T},
  title = {Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {17},
  pages = {1961--1971},
  doi = {10.1200/jco-24-01841}
}
Kostenlos starten →